|1.||Ozdemir, Vural: 1 article (09/2003)|
|2.||Ozdener, Fatih: 1 article (09/2003)|
|3.||Laurent, S: 1 article (05/2000)|
|4.||Gros, C: 1 article (05/2000)|
|5.||Marie, C: 1 article (05/2000)|
|6.||Schwartz, J C: 1 article (05/2000)|
|7.||Lecomte, J M: 1 article (05/2000)|
|8.||Bralet, J: 1 article (05/2000)|
|9.||Boutouyrie, P: 1 article (05/2000)|
|10.||Azizi, M: 1 article (05/2000)|
|1.||Hypertension (High Blood Pressure)
09/01/2003 - "Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe."
05/01/2000 - "After a 4-week placebo run-in period, 57 patients with essential hypertension were included in a randomized double-blind, placebo-controlled, parallel-group study and received orally either fasidotril (100 mg twice daily) or placebo for 6 weeks. "
09/01/2003 - "Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). "
05/01/2000 - "After 42 days, compared with placebo, fasidotril lowered supine systolic and diastolic blood pressures by 7.4/5.4 mm Hg and standing blood pressure by 7.6/6.8 mm Hg. Fasidotril, a dual NEP/ACE inhibitor, was an effective oral antihypertensive agent during chronic treatment in high-renin renovascular rats, normal-renin SHR, and low-renin DOCA-salt hypertensive rats and in patients with essential hypertension."
05/01/2000 - "The aim of this study was to assess the antihypertensive activity of fasidotril, a dual inhibitor of neprilysin (NEP) and angiotensin I-converting enzyme (ACE), in various models of hypertension in rats (spontaneously hypertensive rats [SHR]; renovascular Goldblatt 2-kidney, 1-clip rats; and deoxycorticosterone acetate [DOCA]-salt hypertensive rats) and in patients with mild-to-moderate essential hypertension. "
12/01/1995 - "The aim of the present study was to determine, in rats with myocardial infarction, the systemic and cardiac hemodynamic effects of aladotrilat and of its prodrug, aladotril, both of which display inhibitory activity toward both neutral endopeptidase (NEP, EC. "
03/01/1999 - "Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction."
12/01/1995 - "Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction."
|4.||Cardiomegaly (Heart Hypertrophy)
03/01/1999 - "Cardiac hypertrophy was significantly attenuated by fasidotril for the three infarct sizes. "
03/01/1999 - "In addition to its beneficial effects on survival and cardiac hypertrophy, the lack of hypotensive effect of fasidotril is of interest by reducing the risk of renal hypoperfusion and differentiates the mixed inhibitor from selective ACE inhibitors."
|1.||Neprilysin (Neutral Endopeptidase)
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Surgical Instruments (Clip)